Mobia Medical (NASDAQ:MOBI) Director Buys 16,441 Shares

Key Points

• Director Casey Tansey bought 16,441 Mobia Medical shares at an average price of $12.07, investing approximately $198,443 and increasing their stake by 5.45% to 318,332 shares.
• Mobia Medical reported quarterly revenue of $13.51 million, up 102.4% year over year, but its loss of $1.10 per share missed analysts’ expectations of a $0.83 loss.
• The stock recently traded at $10.95, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $20.75.

Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) Director Casey Tansey purchased 16,441 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $12.07 per share, with a total value of $198,442.87. Following the completion of the purchase, the director owned 318,332 shares of the company's stock, valued at $3,842,267.24. The trade was a 5.45% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Mobia Medical Stock Performance

NASDAQ:MOBI traded down $0.47 during trading hours on Thursday, reaching $10.95. The stock had a trading volume of 71,930 shares, compared to its average volume of 103,512. The company has a market capitalization of $364.53 million and a PE ratio of -0.57. Mobia Medical, Inc. has a 52 week low of $10.19 and a 52 week high of $15.29. The company's 50 day moving average price is $12.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The company's quarterly revenue was up 102.4% on a year-over-year basis. Equities research analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on MOBI shares. Zacks Research upgraded shares of Mobia Medical to a "hold" rating in a research report on Wednesday, June 3rd. Wolfe Research assumed coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set an "outperform" rating on the stock. JPMorgan Chase & Co. upped their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. The Goldman Sachs Group began coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 price target for the company. Finally, Bank of America assumed coverage on Mobia Medical in a research report on Tuesday, June 2nd. They issued a "buy" rating and a $16.00 price target for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source